RT Journal Article
SR Electronic
T1 Response to Comment on “Epigenetic activation of the drug transporter OCT2 sensitizes renal cell carcinoma to oxaliplatin”
JF Science Translational Medicine
FD American Association for the Advancement of Science
SP eaam6298
DO 10.1126/scitranslmed.aam6298
VO 9
IS 391
A1 Zheng, Xiaoli
A1 Liu, Yanqing
A1 Yu, Qinqin
A1 Wang, Hua
A1 Tan, Fuqing
A1 Zhu, Qianying
A1 Yuan, Lingmin
A1 Jiang, Huidi
A1 Zeng, Su
A1 Yu, Lushan
YR 2017
UL http://stm.sciencemag.org/content/9/391/eaam6298.abstract
AB OCT2 plays a key role in synergy between decitabine and oxaliplatin in renal cell carcinoma cell lines.